Patents by Inventor Peter John Ratcliffe

Peter John Ratcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100272726
    Abstract: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.
    Type: Application
    Filed: January 12, 2010
    Publication date: October 28, 2010
    Inventors: Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe, Christopher Joseph Schofield
  • Patent number: 7778779
    Abstract: A method of identifying, screening, characterising or designing a chemical entity, which mimics or binds to FIH, is described. The method comprises comparing a structural model of FIH with a structural model for said chemical entity, wherein said structural model of FIH is derived from structural factors or structural coordinates determined by subjecting to X-ray diffraction measurements a crystal comprising FIH. Such chemical entities may be used in the treatment of a condition associated with increased or decreased HIF levels or activity.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: August 17, 2010
    Assignee: Isis Innovation Limited
    Inventors: Peter John Ratcliffe, Christopher William Pugh, Christopher Joseph Schofield, Kirsty Sarah Hewitson, Jonathan Mark Elkins
  • Patent number: 7709600
    Abstract: The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor ? subunits, by targeting HIF ? for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF ? subunit sequences which may modulate this interaction.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: May 4, 2010
    Assignee: Isis Innovation Limited
    Inventors: Peter John Ratcliffe, Patrick Henry Maxwell, Christopher William Pugh
  • Patent number: 7662854
    Abstract: The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: February 16, 2010
    Assignee: ISIS Innovation Limited
    Inventors: Christopher Joseph Schofield, Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe
  • Patent number: 7638295
    Abstract: A method of identifying an agent which modulates 2-oxoglutarate dependent oxygenase activity, the method comprising contacting a 2-oxoglutarate dependent oxygenase and a test agent in the presence of a substrate comprising one or more ankyrin repeat, or fragment thereof, in conditions under which the substrate is hydroxylated in the absence of the test agent; and determining hydroxylation of the substrate.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: December 29, 2009
    Assignee: Isis Innovation Limited
    Inventors: Christopher Joseph Schofield, Kirsty Sarah Hewitson, Michael Arnold McDonough, Peter John Ratcliffe, Norma Masson, Matthew Edward Cockman
  • Publication number: 20090286858
    Abstract: The present invention is directed to methods of identifying an agent which modulates hydroxylation of hypoxia inducible factor (HIF), comprising contacting a HIF asparagine hydroxylase and a test substance in the presence of a substrate of the hydroxylase under conditions in which asparagine in the substrate is hydroxylated in the absence of the test substance; and determining hydroxylation of the substrate.
    Type: Application
    Filed: April 30, 2009
    Publication date: November 19, 2009
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Christopher William PUGH, Jonathan Mark GLEADLE, Peter John RATCLIFFE, Christopher Joseph SCHOFIELD, Luke Alexander MCNEILL
  • Patent number: 7544480
    Abstract: A method of identifying an agent which modulates hydroxylation of hypoxia inducible factor (HIF), comprises contacting a HIF asparagine hydroxylase and a test substance in the presence of a substrate of the hydroxylase under conditions in which asparagine in the substrate is hydroxylated in the absence of the test substance; and determining hydroxylation of the substrate. Preferably the substrate is a HIF polypeptide comprising HIF-1?, a fragment thereof comprising Asn 803 of HIF-1? or a peptide analogue of HIF-1? or fragment thereof comprising an asparagine equivalent to Asn 803 of HIF-1? and wherein hydroxylation of Asn 803 or of a said equivalent asparagine is determined.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: June 9, 2009
    Assignee: Isis Innovation Limited
    Inventors: Christopher William Pugh, Jonathan Mark Gleadle, Peter John Ratcliffe, Christopher Joseph Schofield, Luke Alexander McNeill
  • Publication number: 20080227848
    Abstract: A method of identifying an agent which modulates 2-oxoglutarate dependent oxygenase activity, the method comprising contacting a 2-oxoglutarate dependent oxygenase and a test agent in the presence of a substrate comprising one or more ankyrin repeat, or fragment thereof, in conditions under which the substrate is hydroxylated in the absence of the test agent; and determining hydroxylation of the substrate.
    Type: Application
    Filed: March 24, 2005
    Publication date: September 18, 2008
    Applicant: Isis Innovation Limited
    Inventors: Christopher Joseph Schofield, Kirsty Sarah Hewitson, Michael Arnold McDonough, Peter John Ratcliffe, Norma Masson, Matthew Edward Cockman
  • Patent number: 6787326
    Abstract: The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor &agr; subunits, by targeting HIF &agr; for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF &agr; subunit sequence which may modulate this interaction.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: September 7, 2004
    Assignee: ISIS Innovation Limited
    Inventors: Peter John Ratcliffe, Patrick Henry Maxwell, Christopher William Pugh
  • Publication number: 20040146964
    Abstract: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 29, 2004
    Inventors: Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe, Christopher Joseph Schofield
  • Patent number: 6265390
    Abstract: Nucleic acid constructs comprising hypoxia response elements in operable linkage with a coding sequence of a gene of interest, and methods for expressing a nucleic acid sequence using the constructs, are disclosed. In particular, such nucleic acid constructs comprise genes encoding prodrug activation systems or cytokines.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: July 24, 2001
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Peter John Ratcliffe, John David Firth, Adrian Llewllyn Harris, Christopher William Pugh, Ian James Stratford
  • Patent number: 5942434
    Abstract: Nucleic acid constructs comprising hypoxia response elements in operable linkage with a coding sequence of a gene of interest are disclosed. In particular, such nucleic acid constructs comprise genes encoding pro-drug activation systems or cytokines.
    Type: Grant
    Filed: December 12, 1996
    Date of Patent: August 24, 1999
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Peter John Ratcliffe, John David Firth, Adrian Llewllyn Harris, Christopher William Pugh, Ian James Stratford